论文部分内容阅读
目的将厄贝沙坦和黄葵胶囊同时应用于慢性肾小球肾炎患者，观察其治疗效果。方法选取在本院接受治疗的50例慢性肾小球肾炎患者，随机分成治疗组(厄贝沙坦+黄葵胶囊联合治疗)和对照组(仅应用厄贝沙坦治疗)，两组同时治疗2个月后，测定患者尿蛋白定量、血清肌酐(SCr)、血尿素氮(BUN)等指标的含量，通过两组指标的对比判定治疗效果。结果治疗组的各项检查结果均优于对照组，尤其是尿蛋定量减少的十分明显，且<0.05。结论将厄贝沙坦+黄葵胶囊同时应用在慢性肾小球肾炎患者的治疗中，可明显控制患者的蛋白尿含量，改善患者的不良状况，值得在此类疾病的治疗中广泛应用。“,”Objective Irbesartan and orka capsule at the same time apply to patients with chronic glomerulonephritis,the curative ef ect.Methods In the hospital treated 50 cases of patients with chronic glomerulonephritis were randomly divided into treatment group (irbesartan+orka capsule combination therapy)and control group (only applies irbesartan),both groups after 2 months of treatment, quantitative measurement,serum creatinine(SCr),content urobilin(BUN)and other indicators of urinary protein determination by comparing the two treatment indicators.Results The inspection results of the treatment group than the control group,especial y urinary protein quantitative reduction is very obvious,and <0.05.Conclusion Irbesartan+orka capsule for application in patients with chronic glomerulonephritis treatment can significantly control the content of proteinuria in patients,to improve the poor condition of the patient,it is worth in the treatment of these diseases widely used.